Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lipid Profile and Weight After Pregnancy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03579667
Recruitment Status : Recruiting
First Posted : July 6, 2018
Last Update Posted : July 11, 2018
Sponsor:
Information provided by (Responsible Party):
Hilde Kristin Brekke, University of Oslo

Brief Summary:
A randomized controlled trial aiming to investigate the effects of diet behavior intervention postpartum on body weight and lipid and metabolite profile in overweight and obese women in Oslo, Norway

Condition or disease Intervention/treatment Phase
Cardiovascular Risk Factor Body Weight Behavioral: Diet intervention Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Lipid Profile and Weight After Pregnancy
Actual Study Start Date : August 15, 2017
Estimated Primary Completion Date : August 15, 2019
Estimated Study Completion Date : August 15, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Experimental: Diet intervention Behavioral: Diet intervention
12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al, Am J Clin Nutr 2012;96:698.), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.

No Intervention: Control



Primary Outcome Measures :
  1. Changes in body weight (kg) between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Measured in light clothing without shoes. Together with measured height (m) will be used to calculate Body Mass Index.

  2. Changes in markers of lipid- and glucose metabolism between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Measured in mmol/l: total cholesterol, low-density lipoprotein, high-density lipoprotein, triglycerides and glucose In percentage: HbA1c In pmol/l: insulin.


Secondary Outcome Measures :
  1. Changes in lipid subclasses (mmol/l), lipoprotein size (nm) and apolipoproteins between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    In g/l: apolipoprotein (apo) B and apo A1. In mmol/l: lipoprotein (a)

  2. Changes in blood pressure, diastolic and systolic between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Measured after 5 min rest, mean of 2 measurements (mmHg)

  3. Changes in waist and hip (cm) circumference between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    A measuring tape specifically designed for waist circumference (Seca) will be used according to a standardized procedure Measurements will be taken against the skin at the approximate midpoint between the lower margin of the last palpable rib and the top of the iliac crest. Hip is measured over the widest point on the buttocks

  4. Changes in body composition (fat free mass in kg and fat mass in kg) between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Measured by Bioelectrical impedance

  5. Changes in circulating inflammation markers such as cytokines, high sensitivity C-Reactive Protein, C-Reactive Protein (CRP) and microCRP between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Measured in mg/l

  6. Changes in plasma metabolomics such as lactate, pyruvate, citrate and amino acids between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Measured in mmol/l

  7. Changes in PBMC (peripheral blood mononuclear cell) gene expression levels of markers of inflammation and lipid metabolism between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Changes in levels of markers of inflammation and lipid metabolism at PBMC gene expression level.

  8. Changes in hemostatic markers such as plasminogen activator inhibitor-1 (PAI-1) antigen and von Willebrand factor (vWF) between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    PAI-1 measured in ng/mL, vWF measured in IU/dl

  9. Changes in hormones such as prolactin, estradiol, progesterone between visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Measured in nmol/l

  10. Changes in markers of micronutrient status such as Hb and vitamin D between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Measured in g/dl (Hb), nm/l (vit D)

  11. Changes in dietary intake and Food Choice by food frequency questionnaire at each of the 3 visits [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    Will be calculated in Norwegian Food database program

  12. Changes in physical activity between visits. [ Time Frame: Visit 1 (8 weeks postpartum, visit 2 (6 months postpartum) and visit 3 (15 months postpartum)] ]
    The physical activity questionnaire describes 4 dimensions of activity (work, transportation, leisure time and exercise). Frequency, intensity or duration of the activity are reported as categorical data (3 or 4 categories).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Women With prepregnant overweight or obesity (BMI>27)
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Women admitted to Adipol, Oslo University Hospital, Norway (outpatient clinic for women with overweight or obesity during pregnancy)

Exclusion Criteria:

  • Twin birth,
  • Non-Norwegian speaking

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03579667


Contacts
Layout table for location contacts
Contact: Hilde k Brekke, PhD +4722851261 h.k.brekke@medisin.uio.no

Locations
Layout table for location information
Norway
University of Oslo Recruiting
Oslo, Norway, 0317
Sponsors and Collaborators
University of Oslo

Layout table for additonal information
Responsible Party: Hilde Kristin Brekke, Professor, University of Oslo
ClinicalTrials.gov Identifier: NCT03579667     History of Changes
Other Study ID Numbers: 2017/450
First Posted: July 6, 2018    Key Record Dates
Last Update Posted: July 11, 2018
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight
Signs and Symptoms